Table 1 Subject characteristics and... | American Society of Hematology

Table 1

Subject characteristics and therapy

Sample	Diagnosis	Age, y	WBC, ×10⁹/L	Hg B, g/dL	HCT, %	Platelets, ×10⁹/L	Cytogenetics	Rx	V617F	Proliferation at 100 nM, %	Inhibited
648	CIMF	66	24.2	8.2	28	455	46,XY,del(13)(q12q14)[10]/46,XY[7]	THAL/PRED	++	47.20	I
694	CIMF	66	23.8	9.2	28	353	46,XY,del(13)(q12q14)[10]/46,XY[7]	EPO	++	37.63	I
695	CIMF	41	7	10.8	33	582	46,XX	ASA	−	66.90	N
699	CIMF	45	3.5	8	24	123	ND	None	−	31.92	I
692	ET	40	5.6	13.9	ND	409	46,XX[11]	HU	+	21.56	I
703	ET	47	8.4	14	41	563	46,XX[25]	HU	+	20.75	I
708	ET	67	6.3	13.5	38	186	ND	HU, ASA	+	39.21	I
713	ET	52	5.2	11.4	34	509	ND	HU, ASA	+	4.22	I
777	ET	73	9.8	ND	48	1065	46,XY[8]	None	+	14.80	I
675	ET	73	4.4	13.2	39	383	46,XX[25]	HU	−	31.86	I
688	ET	75	7.5	14.1	41	1143	46,XY	ASA	−	43.47	I
704	ET	53	6	12.1	35	575	46,XX	HU, ASA	−	34.16	I
707	ET	57	4.5	14		259	ND	HU	−	20	I
706	ET	41	8	11.6	36	602	ND	HU, ASA	−	85.45	N
700	PV	69	8	11.7	33	732	ND	HU, ASA	+	27.89	I
739	PV	56	6.3	13.2	39	369	ND	HU, PB, ASA	+	22.42	I
724	PV	76	8.3	15	44	372	ND	PB, ASA	+	57.75	N
742	PV→ AML	63	53.5	8.7	27	549	ND	HU	++	15.38	I
NBM1	CONTROL	ND	ND	ND	ND	ND	ND	ND	−	60.57	N
NBM2	CONTROL	ND	ND	ND	ND	ND	ND	ND	−	65.49	N
NBM3	CONTROL	ND	ND	ND	ND	ND	ND	ND	−	89.38	N

Sample	Diagnosis	Age, y	WBC, ×10⁹/L	Hg B, g/dL	HCT, %	Platelets, ×10⁹/L	Cytogenetics	Rx	V617F	Proliferation at 100 nM, %	Inhibited
648	CIMF	66	24.2	8.2	28	455	46,XY,del(13)(q12q14)[10]/46,XY[7]	THAL/PRED	++	47.20	I
694	CIMF	66	23.8	9.2	28	353	46,XY,del(13)(q12q14)[10]/46,XY[7]	EPO	++	37.63	I
695	CIMF	41	7	10.8	33	582	46,XX	ASA	−	66.90	N
699	CIMF	45	3.5	8	24	123	ND	None	−	31.92	I
692	ET	40	5.6	13.9	ND	409	46,XX[11]	HU	+	21.56	I
703	ET	47	8.4	14	41	563	46,XX[25]	HU	+	20.75	I
708	ET	67	6.3	13.5	38	186	ND	HU, ASA	+	39.21	I
713	ET	52	5.2	11.4	34	509	ND	HU, ASA	+	4.22	I
777	ET	73	9.8	ND	48	1065	46,XY[8]	None	+	14.80	I
675	ET	73	4.4	13.2	39	383	46,XX[25]	HU	−	31.86	I
688	ET	75	7.5	14.1	41	1143	46,XY	ASA	−	43.47	I
704	ET	53	6	12.1	35	575	46,XX	HU, ASA	−	34.16	I
707	ET	57	4.5	14		259	ND	HU	−	20	I
706	ET	41	8	11.6	36	602	ND	HU, ASA	−	85.45	N
700	PV	69	8	11.7	33	732	ND	HU, ASA	+	27.89	I
739	PV	56	6.3	13.2	39	369	ND	HU, PB, ASA	+	22.42	I
724	PV	76	8.3	15	44	372	ND	PB, ASA	+	57.75	N
742	PV→ AML	63	53.5	8.7	27	549	ND	HU	++	15.38	I
NBM1	CONTROL	ND	ND	ND	ND	ND	ND	ND	−	60.57	N
NBM2	CONTROL	ND	ND	ND	ND	ND	ND	ND	−	65.49	N
NBM3	CONTROL	ND	ND	ND	ND	ND	ND	ND	−	89.38	N

A sample was inhibited (I) if proliferation at 100 nM was less than 50% control (vehicle treated) cells, and not inhibited (N) if proliferation was more than 55% control. By this determination, 15 of 18 MPD samples are inhibited by lestaurtinib versus 0 of 3 control samples. All samples were from different subjects with the exception of samples 648 and 694, which were from the same subject at different points in time. The presence of the JAK2 V617F substitution was determined for each sample, and is listed in column 10.

WBC indicates white blood cells; Hg B, hemoglobin B; HCT, hematocrit; Rx, prescription; −, a sample where the mutation was not detected; +, a sample positive for the mutation; ++, a sample considered homozygous for the V617F mutation, as determined by a complete resistance to restriction enzyme digestion with BsaXI; I, inhibited; and N, not inhibited.

View Large

This Feature Is Available To Subscribers Only